Economic and Safety Advantages of the EZ-IO.
» The True Cost of Vascular
Access
» Potential Economic Benefits
» Patient Safety and Risk Management
» Environmentally Responsible & Cost Effective Waste
» A Proven Partner
The True Cost of
Vascular Access
Central lines are often placed emergently for vascular access – circumventing
sterile protocols intended to protect the patient and hospital from unnecessary
risk.
Intraosseous (IO) vascular access requires significantly fewer resources than central
line insertion, with substantially lower risks, costs and resources.
Even without costs related to infections and other complications, central lines
are costly in terms of time, equipment, and personnel resources.
The IO option provides a decided advantage in all areas. Hospitals
have the potential for substantial cost savings simply by using intraosseous (IO)
insertions to replace emergent central lines.
With increased emphasis on hospital-acquired conditions (HAC’s), the IO option
can result in decreased central line complications and potential decrease in non-reimbursable
conditions. The EZ-IO provides a 100% return on investment after replacement of
one emergent central line.
» View Cost/Benefit Analysis
» Go to top
Potential Economic
Benefits
- Decrease in non-reimbursable hospital-acquired conditions
- Reduced exposure to liability and risk
- Lower number of intensive care admissions
- Lower number of Rapid Response Team patients progressing to code status
- Decreased supply chain costs (reduction of unnecessary central lines)
- Improved efficiency and resource management
- Improved throughput in the Emergency Department
- Rapid patient intervention (preventing further deterioration)
Contact us at cvl@vidacare.com to request
additional detail on cost savings.
» Go to top
Patient
Safety and Risk Management
Historically, intraosseous research has reported very low complication rates of
less than 1%.1 The vast majority of these complications
are minor, such as extravasation and needle removal issues. With the technologically
advanced EZ-IO®, these complications are extremely rare.
Contact us at cvl@vidacare.com to request
additional safety profile information.
» View More Information & Bibliography of Research
» Go to top
Environmentally
Responsible & Cost Effective Waste
EZ-IO needles are 2-3 inches long, and weigh a mere 0.2 ounces, compared to larger
IO devices that weigh between 2–5 ounces. With a far smaller environmental
footprint than any other IO device, the EZ-IO creates minimal medical waste and
less hazardous waste costs for the hospital.
» Go to top
A Proven Partner
EZ-IO Use:
- 90% US Advanced Life Support ambulances
- 50% US Emergency
Departments
- US Military
Established in 2001, Vidacare Corporation is the market
leader in IO technology. Vidacare’s EZ-IO® Intraosseous Infusion
System is used by 90% of advanced life support agencies in the US and over half
of US hospital emergency departments. In addition, EZ-IO is widely used by medical
personnel in the US military forces.
Vidacare: Defining the Field of Intraosseous
Medicine.
» Go to top
References
